Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDGFRB | P09619 | 20/20 | 0.74 |
| ▸ | PDGFRA | P16234 | 13/20 | 0.74 |
| ▸ | KIT | P10721 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2388350 | 0.90 | PDGFRB (0.66) | PDGFRBPDGFRAKIT | |
| SCHEMBL1131894 | 0.89 | PDGFRB (0.57) | PDGFRBPDGFRAKIT | |
| SCHEMBL2390546 | 0.89 | PDGFRB (0.73) | PDGFRBPDGFRAKIT | |
| SCHEMBL1132329 | 0.87 | PDGFRB (0.62) | PDGFRBPDGFRAKIT | |
| SCHEMBL6781045 | 0.87 | PDGFRB (0.89) | PDGFRBPDGFRAKIT | |
| SCHEMBL7155375 | 0.86 | PDGFRB (0.58) | PDGFRBPDGFRAKIT | |
| SCHEMBL1132499 | 0.86 | PDGFRB (0.75) | PDGFRBPDGFRAKIT | |
| SCHEMBL4811163 | 0.86 | PDGFRB (0.56) | PDGFRBPDGFRAKIT | |
| SCHEMBL6709660 | 0.86 | PDGFRB (0.73) | PDGFRBPDGFRAKIT | |
| SCHEMBL1132421 | 0.86 | PDGFRB (0.64) | PDGFRBPDGFRAKIT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8022071-B2 | Nitrogenous heterocyclic compounds | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2011-09-20 | — | — | US | claimed |
| EP-1309568-B1 | [(quinazolin-4-yl)piperazin-4-yl]thiocarboxamide compounds as inhibitors of the phosphorylation of a PDGF receptor | MILLENNIUM PHARM INC (US) | 2011-02-16 | — | — | EP | claimed |
| US-20090176780-A1 | NITROGENOUS HETEROCYCLIC COMPOUNDS | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2009-07-09 | — | — | US | claimed |
| US-20040176594-A1 | Nitrogenous heterocyclic compounds | MILLENNIUM PHARMACEUTICALS, INC. | 2004-09-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040176594-A1 | Nitrogenous heterocyclic compounds | WNK2, NPR1, NPR3 | PDGFRB 9/4885PDGFRA 16/4885KIT 789/4885 |
| US-20090176780-A1 | NITROGENOUS HETEROCYCLIC COMPOUNDS | WNK2, CDK5, WNK1 | PDGFRB 6/4885PDGFRA 4/4885KIT 597/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.